Article

Intravesical Ad-IFNalpha causes marked regression of human bladder cancer growing orthotopically in nude mice and overcomes resistance to IFN-alpha protein.

Department of Genitourinary Medical Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
Molecular Therapy (Impact Factor: 7.04). 10/2004; 10(3):525-32. DOI: 10.1016/j.ymthe.2004.05.027
Source: PubMed

ABSTRACT We have produced prolonged, high local concentrations of interferon in vivo by intravesical instillation of adenoviruses encoding interferon-alpha (Ad-IFNalpha) together with the gene transfer-enhancing agent Syn3. We found sustained interferon protein levels for days, both in normal mouse urothelium and in human bladder cancer cells growing as superficial bladder tumors in nude mice using an orthotopic bladder model developed by us. Tumor burden in the bladder was determined utilizing cancer cells containing the green fluorescent protein. Marked tumor regression was observed following two 1-h exposures of Ad-IFNalpha/Syn3 and little or no cytotoxicity was detected in normal cells. Similar intravesical instillation of clinically relevant concentrations of IFN protein alone or Ad-IFNalpha without Syn3 was ineffective. Surprisingly, in vitro, Ad-IFNalpha also caused caspase-dependent death of bladder cancer cell lines that were resistant to high concentrations of IFN-alpha protein, including the cell line used in vivo. These findings demonstrate that Ad-IFNalpha can overcome resistance to IFN-alpha protein both in vitro and in vivo and support evaluation of intravesical Ad-IFNalpha/Syn3 for the treatment of superficial bladder cancer.

0 Bookmarks
 · 
94 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: A phase l study using intravesical Ad-IFNαSyn3 for patients with bacillus Calmette-Guérin-resistant superficial bladder cancer showed a complete remission (CR) of 43% at 90 days after treatment with high levels of interferon-α (IFNα) being produced. Ad-IFNα kills bladder cancer cells by two apoptotic and one necrotic mechanism that can be measured by soluble forms of cytokeratin 18 (CK18) using M30 and M65 ELISAs, assays for caspase-cleaved (apoptotic) and uncleaved (necrotic) cell death, respectively. Therefore, we determined whether M30 and M65 levels in the urine after treatment could document all three mechanisms of cancer cell kill and also predict having a CR. High levels of both M30 and M65 were found in all patients within 24 h after treatment with all three types of cancer cell death occurring. Moreover, the return of both M30 and M65 levels in the urine to normal levels within 5 days or more after treatment was strongly associated with obtaining a CR (P=0.003). This is the first time that such assays have been used to study response to therapy in the urine of patients with bladder cancer and in the future may prove valuable in predicting clinical outcome.Cancer Gene Therapy advance online publication, 7 February 2014; doi:10.1038/cgt.2014.1.
    Cancer gene therapy 02/2014; · 3.13 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Zusammenfassung Patienten mit Hochrisikoblasentumoren, die nicht auf eine BCG-Immuntherapie ansprechen, stellen eine therapeutische Herausforderung dar. Als Second-line-Therapie wird derzeit häufig eine Kombination aus BCG plus Interferon empfohlen. Da jedoch ein Großteil aggressiv wachsender Tumoren nicht sensibel auf Interferon reagiert, käme anstatt dessen der Einsatz onkolytischer Vesikular-Stomatitisviren (VSV) in Betracht, die speziell Interferon-refraktäre Tumorzellen angreifen. In vitro töteten sowohl Wildtyp-VSV als auch ein attenuierter Subtyp, der eine gesteigerte Tumorselektivität aufweist, bevorzugt aggressiv wachsende, Interferon-resistente Blasentumorzellen. Anschließende In-vivo-Versuche in einem von uns validierten orthotopen Mausmodell konnten die viel versprechende antikanzerogene Aktivität beider Viren nach intravesikaler Gabe eindrucksvoll bestätigen. Obwohl in diesem Modell immunkompromittierte Nacktmäuse verwendet werden, zeigte sich keine virale Toxizität. Zusammenfassend scheinen frühe klinische Studien zur intravesikalen Therapie mit VSV gerechtfertigt.
    Der Urologe 01/2008; 47(9):1145-1151. · 0.46 Impact Factor
  • Drug Delivery System 01/2006; 21(1):46-51.

Full-text (2 Sources)

Download
42 Downloads
Available from
May 23, 2014